Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00450203
Status:
UNKNOWN
Last Update Posted:
2016-12-01
First Post:
2007-03-20
Brief Title:
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
Sponsor:
Professor David Cunningham
Organization:
Medical Research Council
Study Overview
Official Title:
A Randomised Phase IIIII Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and in Selected Centres MRI and PETCT Sub-studies
Status:
UNKNOWN
Status Verified Date:
2016-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ST03
Brief Summary:
RATIONALE Drugs used in chemotherapy such as epirubicin cisplatin and capecitabine work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing Monoclonal antibodies such as bevacizumab and small molecule tyrosine kinase inhibitors such as lapatinib can block tumor growth in different ways Some block the ability of tumor cells to grow and spread Others find tumor cells and help kill them or carry tumor-killing substances to them Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor Lapatinib targets a specific growth receptor HER-2 Chemotherapy together with bevacizumab or lapatinib in HER-2 positive tumours may kill more tumor cells
PURPOSE This randomized phase IIIII trial is studying the side effects and how well giving combination chemotherapy together with bevacizumab works compared with combination chemotherapy alone in treating patients with previously untreated stomach cancer gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery The feasibility study is studying the safety of adding lapatinib to chemotherapy in patients with HER-2 positive previously untreated stomach cancer gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery The feasibility study will also assess the feasibility of timely HER-2 testing and estimate the HER-2 positivity rate in this patient population
PURPOSE This randomized phase IIIII trial is studying the side effects and how well giving combination chemotherapy together with bevacizumab works compared with combination chemotherapy alone in treating patients with previously untreated stomach cancer gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery The feasibility study is studying the safety of adding lapatinib to chemotherapy in patients with HER-2 positive previously untreated stomach cancer gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery The feasibility study will also assess the feasibility of timely HER-2 testing and estimate the HER-2 positivity rate in this patient population
Detailed Description:
OBJECTIVES
Primary
Assess the safety and efficacy of neoadjuvant and adjuvant chemotherapy comprising epirubicin hydrochloride cisplatin and capecitabine with or without bevacizumab in patients with previously untreated resectable gastric gastroesophageal junction or lower oesophageal cancer
Assess the safety of neoadjuvant and adjuvant chemotherapy comprising epirubicin hydrochloride cisplatin and capecitabine with or without lapatinib in patients with HER-2 positive previously untreated resectable gastric gastroesophageal junction or lower oesophageal cancer
OUTLINE This is a multicenter randomized open-label controlled study Patients are randomized to 1 of 4 treatment arms
Arm I and II Patients receive epirubicin hydrochloride IV and cisplatin IV over 4 hours on day 1 and capecitabine orally twice daily on days 1-21 Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity
Patients undergo surgery 5-6 weeks after completion of chemotherapy Patients then receive 3 additional courses of chemotherapy beginning 6-10 weeks after surgery
Arm II Patients receive bevacizumab IV over 30-90 minutes epirubicin hydrochloride IV and cisplatin IV over 4 hours on day 1 and capecitabine orally twice daily on days 1-21 Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity
Patients undergo surgery 5-8 weeks after completion of chemotherapy Patients then receive 3 additional courses of chemotherapy and bevacizumab beginning 6-10 weeks after surgery Patients then receive maintenance therapy comprising bevacizumab IV over 30-90 minutes on day 1 Maintenance therapy repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
Arm IV Patients receive lapatinib orally once daily epirubicin hydrochloride IV and cisplatin IV over 4 hours on day 1 and capecitabine orally twice daily on days 1-21 Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity
Patients undergo surgery 5-8 weeks after completion of chemotherapy Patients then receive 3 additional courses of chemotherapy and lapatinib beginning 6-10 weeks after surgery Patients then receive maintenance therapy comprising lapatinib orally once daily on days 1-21 Maintenance therapy repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
Quality of life is assessed at baseline during treatment and during the follow-up period
After completion of study treatment patients are followed at 9 18 and 27 weeks after the start of course 4 1 year post surgery every 6 months for 2 years and then annually thereafter
PROJECTED ACCRUAL A total of 1063 patients were recruited to the bevacizumab comparison of the study now closed to recruitment and 40 patients with HER-2 positive tumours will be recruited into the ST03 feasibility study
Primary
Assess the safety and efficacy of neoadjuvant and adjuvant chemotherapy comprising epirubicin hydrochloride cisplatin and capecitabine with or without bevacizumab in patients with previously untreated resectable gastric gastroesophageal junction or lower oesophageal cancer
Assess the safety of neoadjuvant and adjuvant chemotherapy comprising epirubicin hydrochloride cisplatin and capecitabine with or without lapatinib in patients with HER-2 positive previously untreated resectable gastric gastroesophageal junction or lower oesophageal cancer
OUTLINE This is a multicenter randomized open-label controlled study Patients are randomized to 1 of 4 treatment arms
Arm I and II Patients receive epirubicin hydrochloride IV and cisplatin IV over 4 hours on day 1 and capecitabine orally twice daily on days 1-21 Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity
Patients undergo surgery 5-6 weeks after completion of chemotherapy Patients then receive 3 additional courses of chemotherapy beginning 6-10 weeks after surgery
Arm II Patients receive bevacizumab IV over 30-90 minutes epirubicin hydrochloride IV and cisplatin IV over 4 hours on day 1 and capecitabine orally twice daily on days 1-21 Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity
Patients undergo surgery 5-8 weeks after completion of chemotherapy Patients then receive 3 additional courses of chemotherapy and bevacizumab beginning 6-10 weeks after surgery Patients then receive maintenance therapy comprising bevacizumab IV over 30-90 minutes on day 1 Maintenance therapy repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
Arm IV Patients receive lapatinib orally once daily epirubicin hydrochloride IV and cisplatin IV over 4 hours on day 1 and capecitabine orally twice daily on days 1-21 Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity
Patients undergo surgery 5-8 weeks after completion of chemotherapy Patients then receive 3 additional courses of chemotherapy and lapatinib beginning 6-10 weeks after surgery Patients then receive maintenance therapy comprising lapatinib orally once daily on days 1-21 Maintenance therapy repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
Quality of life is assessed at baseline during treatment and during the follow-up period
After completion of study treatment patients are followed at 9 18 and 27 weeks after the start of course 4 1 year post surgery every 6 months for 2 years and then annually thereafter
PROJECTED ACCRUAL A total of 1063 patients were recruited to the bevacizumab comparison of the study now closed to recruitment and 40 patients with HER-2 positive tumours will be recruited into the ST03 feasibility study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 003160221001 | OTHER | CTA | None |
| MRC-ST03 | OTHER | None | None |
| EU-20710 | None | None | None |
| ISRCTN46020948 | OTHER | None | None |
| 2006-000811-12 | EUDRACT_NUMBER | None | None |